NIH COVID-19 RESOURCES FOR APPLICANTS AND GRANTEES
Guidance for various aspects of research and grant application processes, as well as FAQs and COVID-19 funding opportunities can be found here.

COVID-19 UPDATES HISTORY WEBPAGE
Relevant updates for applicants and grantees by date can be found here.

FAQ DOCUMENT ON COVID-19 FLEXIBILITIES
Policies and programs affecting the grants process can be found here.

REQUEST FOR INFORMATION: NIDA STRATEGIC PLAN
As part of the strategic planning process, NIDA has issued a Request for Information (RFI) for feedback on an initial outline of their FY 2021-2025 Strategic Plan. Comments will be accepted at NIDAStrategicPlan@nida.nih.gov through August 7, 2020. Read the RFI here.

NIH POSTS COVID-19 GUIDANCE FOR PREPARING FALL 2020 APPLICATIONS
On July 8, the NIH Office of the Director released new guidance for preparing grant applications with fall 2020 due dates, the earliest being September 25. The guidance states that NIH grant applications should not include COVID-19 contingency plans and that reviewers will be instructed to disregard situations due to COVID-19. Read more here.

FINAL 42 CFR PART 2 RULE RELEASED
On July 13, HHS announced the release of a final rule implementing changes to the 42 CFR Part 2 privacy protections for addiction treatment. A list of changes in the final rule is available here.

DRUG OVERDOSE DEATHS HIT ALL-TIME RECORD
The U.S. experienced a record number of drug overdose deaths in 2019, according to newly released federal data, and addiction specialists warn the coronavirus pandemic has only worsened the crisis. Read more here.

FDA ISSUES DRAFT GUIDANCE ON MARIJUANA RESEARCH AND DEVELOPMENT
On July 21, the FDA issued draft guidance outlining the agency’s view on topics related to developing cannabis and cannabis-derived products. Read more here.

AMA OPIOID TASK FORCE PROGRESS REPORT
The number of overdoses related to prescription drugs is declining, but overdoses related to other kinds of opioids, stimulants, heroin and cocaine are all up sharply, according to a report from the American Medical Association’s Opioid Task Force. Read more here.

FDA REQUIRES LABELING CHANGES FOR OPIOIDS
The FDA announced on July 23 that they will require drug makers to include naloxone co-prescribing information in labeling for all opioids and opioid use disorder medications, including buprenorphine, methadone and naltrexone. Read more here.
NIDA REQUEST FOR INFORMATION
NIDA has issued a RFI to solicit input from researchers and health care providers on “Advancing Biomarker Research and Implementation to Personalize Health Services Delivery for Tobacco Use Disorder.” Responses are due on October 1, 2020 and must be submitted to: NIDAbiomarker@nih.gov. The RFI can be found here.

HOUSE PASSES FISCAL 2020 LABOR HHS BILL
On July 31, the House of Representatives passed a second FY2021 minibus spending package, including the FY 2021 Labor-HHS-Education spending bill. The bill includes $47 billion in funding for NIH, including $5 billion in emergency supplemental spending. Read more here.